GSK

GSK plc (LSE/NYSE:GSK) has announced its plans to move to its global headquarters to a new building in central London in 2024. The company is currently based in Brentford, a suburban town in West London. GSK isn’t the only Big Pharma company to announce a headquarters change. In late November, Sanofi (Nasdaq:SNY) moved its home base to…

GSK (LSE/NYSE:GSK) has wrapped up its acquisition of the privately-held biopharma Affinivax.  Cambridge, Massachusetts–based Affinivax has established a vaccine technology platform known as Multiple Antigen Presentation System (MAPS), designed to elicit a strong B-cell and T-cell immune response.  GSK was attracted to Affinivax, given its aim to bolster its portfolio of specialty medicines and vaccines. …

GSK plc (LSE/NYSE: GSK) has demerged from its consumer healthcare division to create the publicly-traded company Haleon Group. Haleon is now one of the world’s largest consumer healthcare companies, while GSK will focus on growing its prescription drug and vaccine businesses.  The company announced the “Haleon” name in February.   In hindsight, GSK would have fared…

GlaxoSmithKline (NYSE:GSK) has long gone by its acronym GSK. Now, the abbreviation is the company’s official name. GlaxoSmithKline had announced its plan to change the name in an earnings announcement in April 27. The London Stock Exchange and the New York Stock Exchange will update the company’s name in “due course,” as the company explained in…

GlaxoSmithKline plc (LSE/NYSE:GSK) has announced that the CEO of Vianai Systems, Vishal Sikka, will join its board as a non-executive director. Vianai Systems is a Bay Area startup focused on ‘human-centered AI.’ Sikka will join after GSK spins off its consumer segment, which it will term ‘Haleon.’ At GSK, Sikka will provide perspective on AI, which…

GlaxoSmithKline plc (GSK) (LSE/NYSE:GSK) is gearing up for the demerger of its consumer healthcare business, which it anticipates will be complicated in July. The company announced that it had enlisted six new directors to the designate board of the spinoff, which will be known as Haleon. In addition to Sir Dave Lewis, whom the GSK named…

In early December 2021, GlaxoSmithKline (LON:GSK) and its partner Vir Biotechnology (NSDQ:VIR) announced that their COVID-19 antibody therapy sotrovimab appeared to retain efficacy against the omicron variant.  Now, demand for sotrovimab is eclipsing supplies of the drug as omicron has fueled a record number of infections in the U.S. and elsewhere.   According to the Wall Street Journal, Glaxo and…

Unilever (LON:ULVR) recently offered to buy GlaxoSmithKline’s (GSK; NYSE:GSK) consumer healthcare unit for £50 billion (about $68 billion). After facing pushback from analysts, investors and credit rating agencies about the deal, Unilever has abandoned the pursuit. In an announcement, the company said it would not raise its offer above £50 billion, noting that it was committed…

Pfizer/BioNTech and Moderna were the first to win emergency use authorization from FDA for COVID-19 vaccines. Johnson & Johnson recently got its own permission to distribute its vaccine. But other Big Pharma companies have struggled to get vaccines to the finish line, including some of the world’s largest vaccine makers such as GlaxoSmithKline, Merck and…

Prominent pharmaceutical companies including Pfizer (NYSE:PFE), Sanofi (NYSE:SNY),  GlaxoSmithKline (NYSE:GSK) and Teva (NYSE: TEVA) intend to raise U.S. prices of more than 300 drugs starting Jan. 1, according to Reuters. But President-elect Joe Biden has vowed to slash drug prices. “Too many Americans cannot afford their prescription drugs, and prescription drug corporations are profiteering off of the pocketbooks of sick individuals,” he wrote in a healthcare…